The Study for

Pregnant Women Expecting an Ectodermal Dysplasia (XLHED) Affected Boy

Now enrolling

Edelife is a clinical study on the safety and possible health benefits of an investigational medicine for those affected by XLHED.

When given to XLHED-affected boys at the right time in the mother’s pregnancy, the investigational medicine should act as a replacement for a missing protein and potentially lead to improved development of a baby’s sweat glands, teeth, and skin.

illustration of a pregnant mother expecting an XLHED-affected boy

Timing is Critical

  • Pregnant women must be enrolled in the clinical trial during the second trimester, no later than pregnancy week 23.
  • The investigational medicine must be given before birth during the development of sweat glands, teeth, skin, and other important structures. No treatments are administered after the child is born.
  • Pregnant women who suspect they have XLHED or are unsure about their XLHED status may be eligible to take part in Edelife.
  • There will be no cost to receive the investigational medicine, including any clinical or travel expenses associated with the clinical study.

Next Steps

If you are interested in taking part in the study or you have questions, please contact a Study Doctor.

Copyright © 2021 – 2024 • Groupe Pierre Fabre All Rights Reserved